FOUNDATIONONE®CDx

PATIENT	TUMOR TYPE	REPORT DATE
Lin, Tzu-I	Brain glioblastoma (GBM)	15 Sep 2022
	COUNTRY CODE	ORDERED TEST #
	TW	ORD-1450680-01

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT
DISEASE Brain glioblastoma (GBM)
NAME Lin, Tzu-I
DATE OF BIRTH 02 August 1949
SEX Male
MEDICAL RECORD # 48811525

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN SITE Brain
SPECIMEN ID S111-31619 B (PF22101)
SPECIMEN TYPE Slide Deck
DATE OF COLLECTION 16 August 2022
SPECIMEN RECEIVED 07 September 2022

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - 1 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

FBXW7 R465H
PDGFRA D842V - subclonal, deletion exons 8-9†
MTAP loss
PTEN K342N
CDKN2A/B CDKN2B loss, CDKN2A loss
TERT promoter -124C>T

2 Disease relevant genes with no reportable alterations: ***EGFR, IDH1***

† See About the Test in appendix for details.

Report Highlights

- Variants with **diagnostic implications** that may indicate a specific cancer type: ***TERT* promoter -124C>T** (p. 8)
- Targeted therapies with potential clinical benefit **approved in another tumor type**: **Everolimus** (p. 9), **Sorafenib** (p. 9), **Temsirolimus** (p. 10)
- Targeted therapies with **potential resistance** based on this patient's genomic findings: ⊗ **Imatinib** (p. 11)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 12)
- Variants with **prognostic implications** for this tumor type that may impact treatment decisions: ***TERT* promoter -124C>T** (p. 8)

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS	
Microsatellite status - MS-Stable	**No therapies or clinical trials.** See Biomarker Findings section	
Tumor Mutational Burden - 1 Muts/Mb	**No therapies or clinical trials.** See Biomarker Findings section	
GENOMIC FINDINGS	**THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)**	**THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)**
FBXW7 - R465H	none	Everolimus
6 Trials see p. 12		Temsirolimus
PDGFRA - D842V - subclonal, deletion exons 8-9	none	Sorafenib
3 Trials see p. 15		***Imatinib*** ⊗
MTAP - loss	none	none
1 Trial see p. 14		
PTEN - K342N	none	none
10 Trials see p. 16		

⊗ *Extensive evidence showing variant(s) in this sample may confer resistance to this therapy*

Electronically signed by Erik Williams, M.D. | 15 September 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

BIOMARKER

Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[1-3], including approved therapies nivolumab and pembrolizumab[4]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[5].

FREQUENCY & PROGNOSIS

Low-level MSI has been reported in 5-9% of glioblastoma (GBM) samples[6-8]. A large-scale study did not find high-level microsatellite instability (MSI-H) in any of 129 GBM samples[6], although a small-scale study reported MSI-H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs[9]. The frequency of MSI has been reported to be increased in relapsed compared to primary GBM[6], in GBMs with a previous lower grade astrocytoma[7], and in giant cell GBM compared to classic GBM[8].

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[10]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[10-12]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[13-15]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[10,12,14-15].

BIOMARKER

Tumor Mutational Burden

RESULT
1 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[16-18], anti-PD-1 therapies[16-19], and combination nivolumab and ipilimumab[20-25]. In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported[16,26-27]. However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti-PD-1[28-29] or anti-PD-L1[30] therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD-1 or PD-L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.

FREQUENCY & PROGNOSIS

Glioblastoma (GBM) harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 4.2% of cases have high TMB (>20 muts/Mb)[31]. For pediatric patients, high TMB has been reported in a subset of high-grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB[32-33]. Increased TMB has been reported to correlate with higher tumor grade in glioma[34] and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD)[28], as well as with shorter OS of patients with diffuse glioma[35].

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[36-37] and cigarette smoke in lung cancer[38-39], treatment with temozolomide-based chemotherapy in glioma[40-41], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[42-46], and microsatellite instability (MSI)[42,45-46]. This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[16,26-30].

Electronically signed by Erik Williams, M.D. | 15 September 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
FBXW7

ALTERATION
R465H

TRANSCRIPT ID
NM_033632

CODING SEQUENCE EFFECT
1394G>A

VARIANT ALLELE FREQUENCY (% VAF)
24.9%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

FBXW7 inactivating alterations may indicate sensitivity to mTOR inhibitors[47-48]. Several case studies reported clinical benefit for patients with FBXW7-mutated cancers, including lung adenocarcinoma[49], renal cell carcinoma[50], and cervical squamous cell carcinoma[51].

FREQUENCY & PROGNOSIS

FBXW7 mutations have been reported in <2% of glioblastoma samples analyzed in the TCGA datasets[52-53]. Significant decreases in FBXW7 expression have been reported in more than 80% of glioblastoma samples studied[54]. Lower FBXW7 expression has been reported to be associated with reduced survival in patients with glioblastoma, and may correlate with tumor aggressiveness[54]. FBXW7 loss has been reported to be important for glioma progression by allowing its oncogenic targets to accumulate[54].

FINDING SUMMARY

FBXW7 encodes the F-box protein subunit of the SCF ubiquitin ligase complex, which targets proteins for degradation[55]. FBXW7 inactivation is associated with chromosomal instability and with stabilization of proto-oncogenes, such as mTOR, MYC, cyclin E, NOTCH, and JUN; FBXW7 is therefore considered a tumor suppressor[55-56]. Alterations such as seen here may disrupt FBXW7 function or expression[56-63].

GENE
PDGFRA

ALTERATION
D842V - subclonal, deletion exons 8-9

TRANSCRIPT ID
NM_006206

CODING SEQUENCE EFFECT
2525A>T

VARIANT ALLELE FREQUENCY (% VAF)
0.90%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of extensive clinical evidence in solid tumors and hematologic cancers, PDGFRA activating alterations are associated with sensitivity to imatinib[64-101]. Sorafenib has shown clinical and preclinical activity against the FIP1L1-PDGFRA fusion in chronic eosinophilic leukemia (CEL) and mutations associated with clinical resistance to imatinib and sunitinib in both CEL and gastrointestinal stromal tumor (GIST)[102-107]. Complete responses to nilotinib have been reported in patients with CEL or hypereosinophilic syndrome with FIP1L1-PDGFRA or activating mutations[80,108-109]; preclinical evidence has reported efficacy of nilotinib in the context of PDGFRA mutations associated with GIST[110-111]. Patients with GIST harboring PDGFRA activating mutations have been reported to derive clinical benefit from treatment with sunitinib[112] or regorafenib[113-114]. Preclinical studies have reported sensitivity of activating PDGFRA mutations and FIP1L1-PDGFRA fusion to dasatinib[104,110]. PDGFRA D842 mutations were reported to be sensitive to avapritinib in clinical[115] and preclinical[115] studies of GIST, and demonstrated sensitivity to ripretinib for 1 patient[116].

— Potential Resistance —

Strong clinical evidence in GIST associates PDGFRA D842V with resistance to imatinib and sunitinib[66,76,101,117-122]; imatinib resistance has also been observed for cases with the D842V mutation in the context of PDGFRA fusions[104,123-125]. Reduced sensitivity to regorafenib has been observed in 1 preliminary clinical study[126], to ponatinib in combination with FIP1L1-PDGFRA fusions in preclinical studies[125,127], and to avapritinib in combination with PDGFRA Y676C, G652E, QGPins, V658A, T674R, or G680R mutations based on limited clinical and preclinical data[128]. It is unclear whether patients with PDGFRA D842V may derive clinical benefit from dasatinib or nilotinib[104,107,110-111,125,129]. Although preclinical and preliminary clinical data in CEL suggest that the D842V mutation renders PDGFRA-rearranged tumors insensitive to sorafenib[104,107,125], patients with D842V-positive GIST have benefited from sorafenib[106,110].

FREQUENCY & PROGNOSIS

PDGFRA mutation has been identified in 5.6% of Grade 3 and 5.4% of Grade 4 astrocytomas, 2.4% of Grade 3 oligodendrogliomas, and 12% (3/25) of gliosarcomas analyzed in COSMIC (Feb 2022)[130]. PDGFRA mutations have been reported in 0-5% of lower grade glioma and glioblastoma samples[52-53,131-136], Ceccarelli et al., 2016; 26824661, Cancer Genome Atlas Research Network., 2015; 26061751, cBio-Johnson et al., 2014; 24336570, cBio-Thomas et al., 2017; 28472509, cBio-Jones et al., 2013; 23817572). A retrospective analysis of TCGA glioma samples reported elevated expression of ERBB3 correlated with PDGFRA expression and co-expression of these genes was an indicator of poor prognosis in a GBM patient cohort[137].

Amplification of PDGFRA has been associated with tumor grade and poor progression-free and overall survival in patients with glioblastoma[138-140]. In addition, PDGFRA amplification has been reported to occur in conjunction with IDH1 mutation in glioblastoma, and both alterations in the same tumor have been associated with poor patient prognosis[140].

FINDING SUMMARY

PDGFRA encodes platelet-derived growth factor receptor alpha (PDGFR-alpha), a tyrosine kinase receptor that, upon binding of cognate ligands (PDGFA or PDGFB), activates several signaling pathways, including PI3K and MAPK[141]. PDGFR aberrations, including point mutations, translocations, amplification, and/or overexpression, have been associated with various malignancies[142]. The PDGFRA exon 18 mutation D842V has been characterized as activating and is associated with clinical resistance to imatinib and sunitinib in GISTs[66,76,101,117-121]. On the basis of preclinical and preliminary clinical evidence, it is unclear whether patients with PDGFRA D842V may benefit from dasatinib or nilotinib and whether sorafenib may be effective against PDGFRA fusion-driven tumors with the D842V mutation[104,107,110-111,125,129,143]. D842V mutation has been shown to be sensitive to avapritinib and regorafenib in several clinical studies of GIST[115,144-145] but with reduced sensitivity to avapritinib when co-occurring with PDGFRA Y676C, G652E, QGPins, V658A, T674R, or G680R mutation[128]. The PDGFRA rearrangement in this tumor results in deletion of exons 8-9. The PDGFRA exon 8-9 deletion mutant was demonstrated to be active in the absence of ligand and has been characterized as transforming[146-147]. This mutant was sensitive to imatinib and the kinase inhibitor vatalanib[147].

Electronically signed by Erik Williams, M.D. | 15 September 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
MTAP

ALTERATION
loss

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

MTAP inactivation produces specific metabolic vulnerabilities that may be sensitive to MAT2A[148-149] or PRMT5 inhibition[149-151]. A Phase 1 trial of MAT2A inhibitor AG-270 reported 1 PR and 2 SDs lasting longer than 6 months for patients with advanced solid tumors displaying MTAP loss[152]. Preclinical data suggest that MTAP loss sensitizes cells to S-adenosyl-L-methionine (SAM)-competitive PRMT5 inhibitors[153], dual PRMT1 and PRMT5 inhibitors[154-156], and PRMT5 inhibitors that selectively bind the PRMT5 when complexed with S-methyl-5'-thioadenosine (MTA), such as MRTX1719, TNG908, and AMG193[157]. In preclinical models, MTAP inactivation showed increased sensitivity to inhibitors of purine synthesis or purine analogs, especially upon addition of exogenous MTA[158-168]. A Phase 2 study of L-alanosine, an inhibitor of adenine synthesis, as a monotherapy for 65 patients with MTAP-deficient cancers reported no responses and SD for 24% (13/55) of patients[169]. Preclinical and limited clinical evidence suggest MTAP deficiency may confer sensitivity to pemetrexed[170].

FREQUENCY & PROGNOSIS

MTAP loss/homozygous deletion as well as loss of expression has been reported in a wide variety of solid tumors and hematologic cancers[171-172]; such events have been correlated with poor prognosis in a variety of cancer types, including hepatocellular carcinoma[173], gastrointestinal stromal tumors[174], mantle cell lymphoma (MCL)[175], melanoma[176-177], gastric cancer[178], myxofibrosarcoma[179], nasopharyngeal carcinoma[180], ovarian carcinoma[171] and non-small cell lung cancer[181]. MTAP loss was not prognostic in pediatric B-cell acute lymphocytic leukemia[182] or in astrocytoma[183]. However, MTAP has also been reported to be overexpressed in colorectal cancer (CRC) samples[184], and MTAP retention is thought to be important for prostate cancer growth due to continuous supply of SAM[185]. Germline SNPs in MTAP have been correlated with the development of cutaneous melanoma[186-187], esophageal cancer[188-189], osteosarcoma[190], and CRC[191].

FINDING SUMMARY

MTAP encodes S-methyl-5'-thioadenosine (MTA) phosphorylase, a tumor suppressor involved in polyamine metabolism and methionine synthesis, although its enzymatic function is dispensable for its tumor suppressor activity[192-193]. Decreased expression of MTAP leads to MTA accumulation within tumor cells and their microenvironment[173,194-195], thereby reducing intracellular arginine methylation[149-151] and altering cell signaling[195-196]. MTAP is located at 9p21, adjacent to CDKN2A and CDKN2B, with which it is frequently co-deleted in various cancers. Other alterations in MTAP are rare and have not been extensively characterized.

GENE
PTEN

ALTERATION
K342N

TRANSCRIPT ID
NM_000314

CODING SEQUENCE EFFECT
1026G>C

VARIANT ALLELE FREQUENCY (% VAF)
53.8%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

PTEN loss or mutation leads to activation of the PI3K-AKT-mTOR pathway and may predict sensitivity to inhibitors of this pathway[197-200]. Clinical studies in glioblastoma have not observed an association between PTEN deficiency and response to everolimus or temsirolimus[201-203]. Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors[204-208], and clinical benefit has been observed for patients with PTEN-altered breast cancer including triple negative breast cancer[209], ovarian cancer[210], uterine leiomyosarcoma[211], and endometrial cancer[208] treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity[212-213].

FREQUENCY & PROGNOSIS

Studies in the literature have indicated that PTEN alterations (mutation or homozygous deletion) occur most frequently in glioblastoma (GBM), less frequently in anaplastic astrocytoma, and rarely in lower grade glioma subtypes including low grade astrocytoma, oligodendroglioma, oligoastrocytoma, and ependymoma[214-221]. One study detected PTEN mutation in 42% (97/232) and loss in 10% (24/232) of IDH-wildtype GBM samples analyzed[222]. In the TCGA dataset, PTEN mutation was observed in 23% of GBM cases and PTEN deletion was reported in 7% of cases[52], while in the Lower Grade Glioma TCGA dataset, PTEN mutation was observed in 4% of cases and homozygous deletion observed in 1.2% of cases[223]. Decreased PTEN expression is associated with the higher grade GBM tumors[224]. Loss of PTEN correlated with significantly worse prognosis in all grades of gliomas[218,225].

FINDING SUMMARY

PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis[198]. Alterations such as seen here may disrupt PTEN function or expression[220,226-266].

POTENTIAL GERMLINE IMPLICATIONS

PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte-Duclos disease (LD), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and Proteus-like syndrome[267-268]. The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients[267,269]. The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder[267]. Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.

GENE
CDKN2A/B

ALTERATION
CDKN2B loss, CDKN2A loss

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib[270-273]. Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib[274] and palbociclib treatment[275-276]. However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents[277-283]; it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors[284-285], the clinical relevance of p14ARF as a predictive biomarker is not clear. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib[278,280-281,286-288].

FREQUENCY & PROGNOSIS

Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas[289] and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)[52] than in those with lower grade gliomas (6%)[290]. In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM)[139,291-292]. A study found homozygous deletion of both p16INK4a and p14ARF in 26% (13/50) of glioblastomas (GBMs); 18% (9/50) of cases showed homozygous deletion of the p14ARF-encoding locus alone[293]. One study detected CDKN2A/B loss in 69% (161/232) and mutation in 2.6% (6/232) of IDH-wildtype GBM samples analyzed[222]. Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples[294]. Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in GBM and likely serves as an early event in GBM progression[139,295]. In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared to patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter overall survival in pilocytic astrocytomas[296-297].

FINDING SUMMARY

CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b[298-299]. Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth-suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6-cyclin-Rb pathway and loss of cell cycle control[300-301]. The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition[302-303]. One or more alterations observed here are predicted to result in p16INK4a loss of function[304-325]. One or more alterations seen here are predicted to result in p14ARF loss of function[308,325-328]. CDKN2B alterations such as seen here are predicted to inactivate p15INK4b[329].

POTENTIAL GERMLINE IMPLICATIONS

Germline CDKN2A mutation is associated with melanoma-pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer[330]. Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma[331-332]. CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases[333-335]. CDKN2A alteration has also been implicated in familial melanoma-astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors[336-338]. In the appropriate clinical context, germline testing of CDKN2A is recommended.

GENE
TERT

ALTERATION
promoter -124C>T

TRANSCRIPT ID
NM_198253

CODING SEQUENCE EFFECT
-124C>T

VARIANT ALLELE FREQUENCY (% VAF)
23.9%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor-associated antigen and antisense oligonucleotide- or peptide-based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials[339]; however, in one preclinical study, the combination of a TERT peptide vaccine and anti-CTLA-4 therapy suppressed tumor growth[340]. A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non-small cell lung cancer reported no improvement in PFS or OS[341].

FREQUENCY & PROGNOSIS

TERT promoter mutations have been reported in 51-59% of gliomas[342-343], most frequently in glioblastoma (GBM, 54-84%), gliosarcoma (81%), oligodendroglioma (78%), and historically in oligoastrocytomas (25-31%) but less frequently in lower grade astrocytomas (10-18%) and in only 1% of ependymomas[342-346]. In patients with glioblastoma (GBM), the prevalence of TERT promoter mutation is lower in pediatric primary GBM (11%) and adult secondary GBM (28%) compared with adult primary GBM (58-83%)[342,344]. One study detected TERT promoter mutations in 78% (181/232) of IDH-wildtype GBM samples analyzed[222]. TERT promoter mutation has been shown to be significantly associated with increased TERT gene expression in astrocytoma, oligodendroglioma, and GBM[347]. TERT promoter mutations significantly associate with poor prognosis in patients with GBM, although this correlation may be due to the association with primary GBM as opposed to IDH-positive secondary GBM[342,344,347-348]. In the context of IDH-wildtype glioma, TERT mutations are associated with reduced OS (NCCN CNS Cancers Guidelines, v1.2022).

FINDING SUMMARY

Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length[349]. Activation of TERT is a hallmark of cancer, being detected in up to 80-90% of malignancies and absent in quiescent cells[350-352]. Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at -124 bp and -146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)[353-355], as well as tandem mutations at positions –124/–125 bp and –138/–139 bp[353].

POTENTIAL DIAGNOSTIC IMPLICATIONS

TERT mutations are associated with 1p/19q co-deletion in oligodendrogliomas, and are highly recurrent in IDH/ATRX-wildtype glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v1.2022)[356]. The presence of EGFR gene amplification or TERT promoter mutations are indicative of diffuse astrocytic glioma with molecular features of glioblastoma, WHO grade 4 in IDH1/2-wildtype tumors (NCCN CNS Cancers Guidelines, v1.2022)[357].

Everolimus

Assay findings association

FBXW7
R465H

AREAS OF THERAPEUTIC USE

Everolimus is an orally available mTOR inhibitor that is FDA approved to treat renal cell carcinoma (RCC) following antiangiogenic therapy; pancreatic neuroendocrine tumors; and well-differentiated non-functional neuroendocrine tumors of the lung or gastrointestinal tract. Everolimus is also approved to treat either renal angiomyolipoma or subependymal giant cell astrocytoma in association with tuberous sclerosis complex (TSC). Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of several case reports describing clinical benefit for patients with FBXW7-mutated cancers treated with mTOR inhibitors, including lung adenocarcinoma[49], renal cell carcinoma[50], and cervical squamous cell carcinoma[358], FBXW7 loss or inactivation may predict sensitivity to everolimus or temsirolimus.

SUPPORTING DATA

A Phase 2 trial of radiotherapy (RT), temozolomide (TMZ), and bevacizumab followed by everolimus and bevacizumab reported that 61% (31/51) of patients with newly diagnosed glioblastoma had objective responses with a median progression-free survival (PFS) of 11.3 months and median overall survival (OS) of 13.9 months[359]. A Phase 2 study of everolimus combined with TMZ and RT for the treatment of newly diagnosed glioblastoma reported a median PFS of 6.4 months and median OS of 15.8 months[360]. A Phase 1 trial of everolimus plus TMZ for patients with newly diagnosed or progressive glioblastoma reported partial responses (PR) in 11% (3/28) and stable disease (SD) in 57% (16/28) of cases[203]. A pilot study of everolimus with gefitinib in patients with recurrent glioblastoma reported 14% (3/22) PRs, 36% (8/22) SDs, and median PFS and OS of 2.6 months and 5.8 months, respectively[202]. Everolimus treatment achieved SD in 45% (5/11) of pediatric patients with heavily pretreated low-grade CNS tumors; median PFS of these responses was 14 months[361]. Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors[362], a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months[363].

Sorafenib

Assay findings association

PDGFRA
D842V - subclonal, deletion exons 8-9

AREAS OF THERAPEUTIC USE

Sorafenib is a kinase inhibitor that targets the RAF kinases, KIT, FLT3, RET, VEGFRs, and PDGFRs. It is FDA approved for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and recurrent or metastatic differentiated thyroid carcinoma. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical responses in patients with GIST, PDGFRA activating mutations may predict sensitivity to sorafenib[106,364]. Although 4 patients with PDGFRA D842V-positive GIST have been reported to progress on sorafenib[126], 3 studies observed PRs for 4/10 and SD for 6/10 patients[364-365] ; this sensitivity is supported by preclinical data[110]. Based on preclinical and preliminary clinical evidence, PDGFRA D842V may confer reduced sensitivity to sorafenib[104,107,110,120,125-126,129,366] . Therefore, it is unclear whether this therapeutic strategy would be relevant here.

SUPPORTING DATA

Phase 2 studies of sorafenib plus temozolomide report limited activity in patients with relapsed glioblastoma multiforme (GBM)[367]. A Phase 1/2 trial of temsirolimus in combination with sorafenib in patients with glioblastoma was terminated at the Phase 2 interim analysis after patients failed to meet the primary endpoint of 6 month progression-free survival[368]. A Phase 2 trial of sorafenib and erlotinib in glioblastoma also did not meet its primary endpoint, and erlotinib clearance was increased by the addition of sorafenib[369]. In a Phase 1 trial in patients with high-grade glioma, the combination of sorafenib with radiation therapy (RT) and temozolomide (TMZ) resulted in increased toxicity and did not result in significant improvement in clinical efficacy compared with RT and TMZ alone[370]. In a clinical study of sorafenib in pediatric patients with low-grade astrocytoma, one patient achieved a partial response (PR), one had stable disease (SD), and 9 patients had progressive disease; this study was terminated early due to unexpectedly high disease progression rates[371].

Temsirolimus

Assay findings association

FBXW7
R465H

AREAS OF THERAPEUTIC USE

Temsirolimus is an intravenous mTOR inhibitor that is FDA approved for the treatment of advanced renal cell carcinoma. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of several case reports describing clinical benefit for patients with FBXW7-mutated cancers treated with mTOR inhibitors, including lung adenocarcinoma[49], renal cell carcinoma[50], and cervical squamous cell carcinoma[358], FBXW7 loss or inactivation may predict sensitivity to everolimus or temsirolimus.

SUPPORTING DATA

A Phase 1, dose-escalation trial combining temsirolimus and radiation/temozolomide therapy, with or without adjuvant temozolomide monotherapy, in patients with newly diagnosed glioblastoma reported no clinical responses but 24/25 patients experienced a period of stable disease; increased infection rates were noted with this regimen[372]. A Phase 1/2 trial of temsirolimus in combination with sorafenib in glioblastoma was terminated at the Phase 2 interim analysis after patients failed to meet the primary endpoint of 6 month progression-free survival; significant toxicity was also observed in the combination therapy, even at low doses of temsirolimus[368]. A Phase 2 study showed that addition of temsirolimus to bevacizumab therapy in patients with recurrent glioblastoma did not add clinical benefit[373]. A Phase 2 clinical trial of temsirolimus in pediatric glioma reported disease stabilization in 7/17 patients including one patient with anaplastic astrocytoma[374]. A Phase 1/2 study of temsirolimus in combination with erlotinib reported 6% (1/16) complete responses, 6% (1/16) partial responses, and 12.5% (2/16) instances of stable disease in patients with anaplastic glioma[375].

Imatinib

Resistance of variant(s) to associated therapy is likely

Assay findings association

PDGFRA
D842V - subclonal, deletion exons 8-9

AREAS OF THERAPEUTIC USE

Imatinib targets the BCR-ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT-positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/ myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of strong clinical evidence, PDGFRA activating mutations[66,71-72,76,101], fusions[65,69,75,77,85,88,90,94,97,376], and expression[74] may predict sensitivity to imatinib. However, with the exception of rare cases of response[118,377], extensive clinical and preclinical data in GIST indicate that PDGFRA D842V confers resistance to imatinib, with progressive disease reported for 78% (61/78) of patients from various studies[66,76,101,117-121,126,366,377-379]; several studies observed shorter median progression-free survival with imatinib for patients with PDGRA D842V than for patients with other PDGFRA mutations (2.8-8.0 vs. 24-30 months)[66,101,377].

SUPPORTING DATA

In a clinical study where patients with recurrent glioblastoma were given imatinib, 2/24 patients achieved a PR, 10 patients reported SD, and median OS and PFS was observed to be 6.2 and 3 months, respectively[380]. However, other Phase 2 clinical trials of imatinib have reported no anti-tumor activity, with a study of 231 patients with glioblastoma reporting a radiographic response rate of only 3.4%[381-382]. In another Phase 2 study, imatinib plus hydroxyurea was shown to be well tolerated among patients with recurrent/progressive low-grade glioma, but had negligible antitumor activity[383].

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or, visit https://www.foundationmedicine.com/genomic-testing#support-services.

GENE
FBXW7

ALTERATION
R465H

RATIONALE
Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.

NCT03239015

PHASE 2

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

TARGETS
EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6

LOCATIONS: Shanghai (China)

NCT04803318

PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK

LOCATIONS: Guangzhou (China)

NCT05125523

PHASE 1

A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors

TARGETS
mTOR

LOCATIONS: Tianjin (China)

NCT03158389

PHASE 1/2

NCT Neuro Master Match - N^2M^2 (NOA-20)

TARGETS
ALK, RET, CDK4, CDK6, mTOR, MDM2, PD-L1, SMO

LOCATIONS: Berlin (Germany), Dresden (Germany), Regensburg (Germany), Bochum (Germany), Frankfurt am Main (Germany), Essen (Germany), Mainz (Germany), Heidelberg (Germany), Cologne (Germany), Mannheim (Germany)

NCT01582191

PHASE 1

A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer

TARGETS
mTOR, EGFR, SRC, RET, VEGFRs

LOCATIONS: Texas

NCT03203525

PHASE 1

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

TARGETS
VEGFA, mTOR

LOCATIONS: Texas

GENE
MTAP

ALTERATION
loss

RATIONALE
MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.

NCT05245500

PHASE 1/2

Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

TARGETS
PRMT5-MTA

LOCATIONS: Colorado, Massachusetts, New York, Tennessee, Texas

GENE
PDGFRA

ALTERATION
D842V - subclonal, deletion exons 8-9

RATIONALE
PDGFRA activating mutations may predict sensitivity to certain PDGFRA-targeted therapies. PDGFRA D842V predicts resistance to imatinib and sunitinib and may confer reduced sensitivity to regorafenib or ponatinib in the context of FIP1L1-PDGFRA fusion. Therefore, it is unclear whether dasatinib or nilotinib may provide clinical benefit for patients with PDGFRA D842V and whether sorafenib may be effective against PDGFRA-rearranged tumors with the D842V mutation. On the basis of limited clinical and preclinical evidence, D842V in combination with co-occurring mutations Y676C, G652E, QGPins, V658A, T674R, or G680R may have reduced sensitivity to avapritinib.

NCT03970447

PHASE 2/3

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

TARGETS
BRAF, VEGFRs, RET, KIT

LOCATIONS: Utah, Michigan, New York

NCT05159245

PHASE 2

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

TARGETS
BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD-L1, MEK, CDK4, CDK6

LOCATIONS: Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)

NCT04771520

PHASE 2

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

TARGETS
KIT, PDGFRA

LOCATIONS: Texas

GENE
PTEN

ALTERATION
K342N

RATIONALE
PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.

NCT04644068

PHASE 1/2

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

TARGETS
ERBB2, TROP2, PARP

LOCATIONS: Shanghai (China), Seoul (Korea, Republic of), Chongqing (China), Chuo-ku (Japan), Koto-ku (Japan), Melbourne (Australia), Warszawa (Poland), Gdynia (Poland), Grzepnica (Poland), Budapest (Hungary)

NCT04341259

PHASE 1

A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.

TARGETS
AKTs

LOCATIONS: Shanghai City (China)

NCT02264678

PHASE 1/2

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents

TARGETS
ATR, PARP, PD-L1

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)

NCT04740190

PHASE 2

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

TARGETS
PARP

LOCATIONS: Hong Kong (Hong Kong)

NCT04001569

PHASE 1/2

AZD8186 and Paclitaxel in Advanced Gastric Cancer

TARGETS
PI3K-beta

LOCATIONS: Seongnam-si (Korea, Republic of)

NCT05035745

PHASE 1/2

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

TARGETS
XPO1, PARP

LOCATIONS: Singapore (Singapore)

NCT03772561

PHASE 1

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

TARGETS
PARP, AKTs, PD-L1

LOCATIONS: Singapore (Singapore)

NCT04614909

PHASE NULL

Phase 0/2 Study of Pamiparib in Newly Diagnosed and rGBM

TARGETS
PARP

LOCATIONS: Arizona

NCT05076513

PHASE NULL

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

TARGETS
PARP

LOCATIONS: Arizona

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

ERBB2	*MERTK*	*MITF*	*TSC1*
A270S	L514S	V13A	R1062Q

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	*ACVR1B*	*AKT1*	*AKT2*	*AKT3*	*ALK*	*ALOX12B*	*AMER1 (FAM123B or WTX)*	
APC	*AR*	*ARAF*	*ARFRP1*	*ARID1A*	*ASXL1*	*ATM*	*ATR*	*ATRX*
AURKA	*AURKB*	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*
BCL6	*BCOR*	*BCORL1*	*BRAF*	*BRCA1*	*BRCA2*	*BRD4*	*BRIP1*	*BTG1*
BTG2	*BTK*	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	*CCND1*	*CCND2*
CCND3	*CCNE1*	*CD22*	*CD274 (PD-L1)*	*CD70*	*CD79A*	*CD79B*	*CDC73*	*CDH1*
CDK12	*CDK4*	*CDK6*	*CDK8*	*CDKN1A*	*CDKN1B*	*CDKN2A*	*CDKN2B*	*CDKN2C*
CEBPA	*CHEK1*	*CHEK2*	*CIC*	*CREBBP*	*CRKL*	*CSF1R*	*CSF3R*	*CTCF*
CTNNA1	*CTNNB1*	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*	*DDR2*
DIS3	*DNMT3A*	*DOT1L*	*EED*	*EGFR*	*EMSY (C11orf30)*	*EP300*	*EPHA3*	*EPHB1*
EPHB4	*ERBB2*	*ERBB3*	*ERBB4*	*ERCC4*	*ERG*	*ERRFI1*	*ESR1*	*EZH2*
FANCA	*FANCC*	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*
FGF19	*FGF23*	*FGF3*	*FGF4*	*FGF6*	*FGFR1*	*FGFR2*	*FGFR3*	*FGFR4*
FH	*FLCN*	*FLT1*	*FLT3*	*FOXL2*	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*
GATA6	*GID4 (C17orf39)*	*GNA11*	*GNA13*	*GNAQ*	*GNAS*	*GRM3*	*GSK3B*	*H3-3A (H3F3A)*
HDAC1	*HGF*	*HNF1A*	*HRAS*	*HSD3B1*	*ID3*	*IDH1*	*IDH2*	*IGF1R*
IKBKE	*IKZF1*	*INPP4B*	*IRF2*	*IRF4*	*IRS2*	*JAK1*	*JAK2*	*JAK3*
JUN	*KDM5A*	*KDM5C*	*KDM6A*	*KDR*	*KEAP1*	*KEL*	*KIT*	*KLHL6*
KMT2A (MLL)	*KMT2D (MLL2)*	*KRAS*	*LTK*	*LYN*	*MAF*	*MAP2K1 (MEK1)*	*MAP2K2 (MEK2)*	*MAP2K4*
MAP3K1	*MAP3K13*	*MAPK1*	*MCL1*	*MDM2*	*MDM4*	*MED12*	*MEF2B*	*MEN1*
MERTK	*MET*	*MITF*	*MKNK1*	*MLH1*	*MPL*	*MRE11 (MRE11A)*	*MSH2*	*MSH3*
MSH6	*MST1R*	*MTAP*	*MTOR*	*MUTYH*	*MYC*	*MYCL (MYCL1)*	*MYCN*	*MYD88*
NBN	*NF1*	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2*	*NOTCH3*
NPM1	*NRAS*	*NSD2 (WHSC1 or MMSET)*		*NSD3 (WHSC1L1)*	*NT5C2*	*NTRK1*	*NTRK2*	*NTRK3*
P2RY8	*PALB2*	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1 (PD-1)*	*PDCD1LG2 (PD-L2)*
PDGFRA	*PDGFRB*	*PDK1*	*PIK3C2B*	*PIK3C2G*	*PIK3CA*	*PIK3CB*	*PIK3R1*	*PIM1*
PMS2	*POLD1*	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*
PRKN (PARK2)	*PTCH1*	*PTEN*	*PTPN11*	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*
RAD51B	*RAD51C*	*RAD51D*	*RAD52*	*RAD54L*	*RAF1*	*RARA*	*RB1*	*RBM10*
REL	*RET*	*RICTOR*	*RNF43*	*ROS1*	*RPTOR*	*SDHA*	*SDHB*	*SDHC*
SDHD	*SETD2*	*SF3B1*	*SGK1*	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*	*SMO*
SNCAIP	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*	*STAT3*
STK11	*SUFU*	*SYK*	*TBX3*	*TEK*	*TENT5C (FAM46C)*		*TET2*	*TGFBR2*
TIPARP	*TNFAIP3*	*TNFRSF14*	*TP53*	*TSC1*	*TSC2*	*TYRO3*	*U2AF1*	*VEGFA*
VHL	*WT1*	*XPO1*	*XRCC2*	*ZNF217*	*ZNF703*			

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	*BCL2*	*BCR*	*BRAF*	*BRCA1*	*BRCA2*	*CD74*	*EGFR*	*ETV4*
ETV5	*ETV6*	*EWSR1*	*EZR*	*FGFR1*	*FGFR2*	*FGFR3*	*KIT*	*KMT2A (MLL)*
MSH2	*MYB*	*MYC*	*NOTCH2*	*NTRK1*	*NTRK2*	*NUTM1*	*PDGFRA*	*RAF1*
RARA	*RET*	*ROS1*	*RSPO2*	*SDC4*	*SLC34A2*	*TERC**	*TERT***	*TMPRSS2*

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Homologous Recombination status
Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. CE

ABOUT FOUNDATIONONE CDX

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLE

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for *ERBB2* and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fractional-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by

analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.

2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
3. Homologous Recombination status may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas (Coleman et al., 2017; 28916367). Samples with deleterious *BRCA1/2* alteration and/or Loss of Heterozygosity (LOH) score ≥ 16% will be reported as "HRD Positive" and samples with absence of these findings will be reported as "HRD Not Detected," agnostic of potential secondary *BRCA1/2* reversion alterations. Certain potentially deleterious missense or small in-frame deletions in *BRCA1/2* may not be classified as deleterious and, in the absence of an elevated LOH profile, samples with such mutations may be classified as "HRD Not Detected." A result of "HRD Not Detected" does not rule out the presence of a *BRCA1/2* alteration or an elevated LOH profile outside the assay performance characteristic limitations.
4. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
5. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
6. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
7. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/ report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	**%CV***
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

**Interquartile Range = 1st Quartile to 3rd Quartile*

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's

tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, CBL, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2*, and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

REFERENCE SEQUENCE INFORMATION

Sequence data is mapped to the human genome, Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19.

MR Suite Version (RG) 7.1.0

The median exon coverage for this sample is 806x

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Martinez R, et al. Oncology (2004) pmid: 15331927
7. Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285
8. Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554
9. Szybka M, et al. Clin. Neuropathol. () pmid: 12908754
10. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
11. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
12. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
13. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
14. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
15. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
16. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
17. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
18. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
19. Cristescu R, et al. Science (2018) pmid: 30309915
20. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
21. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
22. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
23. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
24. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
25. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
26. Zhao J, et al. Nat. Med. (2019) pmid: 30742119
27. Touat M, et al. Nature (2020) pmid: 32322066
28. Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570
29. Johanns TM, et al. Cancer Discov (2016) pmid: 27683556
30. Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642
31. Chalmers ZR, et al. Genome Med (2017) pmid: 28420421
32. Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112
33. Johnson A, et al. Oncologist (2017) pmid: 28912153
34. Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864
35. Wang L, et al. BMC Cancer (2020) pmid: 32164609
36. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
37. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
38. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
39. Rizvi NA, et al. Science (2015) pmid: 25765070
40. Johnson BE, et al. Science (2014) pmid: 24336570
41. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
42. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
43. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
44. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
45. Nature (2012) pmid: 22810696
46. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
47. Mao JH, et al. Science (2008) pmid: 18787170
48. Yang H, et al. Oncotarget (2015) pmid: 25749036
49. Villaruz LC, et al. Lung Cancer (2014) pmid: 24360397
50. Olson D, et al. Clin Genitourin Cancer (2016) pmid: 27079472
51. Kulkarni et al., 2020; https://doi.org/10.1016/j.ygyno.2020.05.244
52. Brennan CW, et al. Cell (2013) pmid: 24120142
53. Nature (2008) pmid: 18772890
54. Hagedorn M, et al. Cell Div (2007) pmid: 17326833
55. Welcker M, et al. Nat. Rev. Cancer (2008) pmid: 18094723
56. Akhoondi S, et al. Cancer Res. (2007) pmid: 17909001
57. Welcker M, et al. Genes Dev. (2013) pmid: 24298052
58. Welcker M, et al. Cell Div (2007) pmid: 17298674
59. Strohmaier H, et al. Nature (2001) pmid: 11565034
60. Pashkova N, et al. Mol. Cell (2010) pmid: 21070969
61. O'Neil J, et al. J. Exp. Med. (2007) pmid: 17646409
62. Malyukova A, et al. Leukemia (2013) pmid: 23228967
63. Thompson BJ, et al. J. Exp. Med. (2007) pmid: 17646408
64. Arefi M, et al. Int. J. Hematol. (2012) pmid: 22806436
65. Baccarani M, et al. Haematologica (2007) pmid: 17666373
66. Cassier PA, et al. Clin. Cancer Res. (2012) pmid: 22718859
67. Chalmers ZR, et al. Blood Cancer J (2015) pmid: 25658984
68. Cools J, et al. N. Engl. J. Med. (2003) pmid: 12660384
69. Curtis CE, et al. Br. J. Haematol. (2007) pmid: 17555450
70. Debiec-Rychter M, et al. Eur. J. Cancer (2004) pmid: 15010069
71. Dileo P, et al. Int. J. Cancer (2011) pmid: 20473908
72. Fanta PT, et al. J. Clin. Oncol. (2015) pmid: 24638008
73. Florian S, et al. Leuk. Res. (2006) pmid: 16406018
74. Frenard C, et al. JAAD Case Rep (2016) pmid: 27051816
75. Griffin JH, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808148
76. Heinrich MC, et al. J. Clin. Oncol. (2003) pmid: 14645423
77. Helbig G, et al. Br. J. Haematol. (2009) pmid: 19120352
78. Helbig G, et al. Am. J. Hematol. (2014) pmid: 24009127
79. Hus M, et al. Leuk. Res. (2011) pmid: 21093052
80. Ikezoe T, et al. Leuk. Res. (2010) pmid: 20303172
81. Intermesoli T, et al. Br. J. Haematol. (2009) pmid: 19735261
82. Jain N, et al. Leuk. Res. (2009) pmid: 19013640
83. Jovanovic JV, et al. Blood (2007) pmid: 17299092
84. Kang HJ, et al. Acta Oncol (2012) pmid: 22150077
85. Klion AD, et al. Blood (2004) pmid: 14504092
86. Kobayashi M, et al. Respirology (2009) pmid: 19192229
87. Kocáková I, et al. Klin Onkol (2014) pmid: 24635438
88. Metzgeroth G, et al. Br. J. Haematol. (2008) pmid: 18950453
89. Murayama Y, et al. World J Gastrointest Oncol (2012) pmid: 22645636
90. Ogbogu PU, et al. J. Allergy Clin. Immunol. (2009) pmid: 19910029
91. Ohnishi H, et al. Br. J. Haematol. (2006) pmid: 16856885
92. Pardanani A, et al. Blood (2003) pmid: 12842979
93. Pardanani A, et al. Blood (2004) pmid: 15284118
94. Qu SQ, et al. Oncotarget (2016) pmid: 27120808
95. Score J, et al. Leukemia (2006) pmid: 16498388
96. Shah S, et al. J Hematol Oncol (2014) pmid: 24669761
97. Sugimoto Y, et al. Cancer Genet (2015) pmid: 26319757
98. Volz HC, et al. Int. J. Cardiol. (2011) pmid: 20609486
99. von Bubnoff N, et al. Leukemia (2005) pmid: 15618966
100. Walz C, et al. Genes Chromosomes Cancer (2006) pmid: 16845659
101. Yoo C, et al. Cancer Res Treat (2016) pmid: 26130666
102. Al-Riyami AZ, et al. Leuk. Lymphoma (2013) pmid: 23157309
103. Lierman E, et al. Blood (2006) pmid: 16645167
104. Lierman E, et al. Leukemia (2009) pmid: 19212337
105. Metzgeroth G, et al. Leukemia (2012) pmid: 21818111
106. Roubaud G, et al. Ann. Oncol. (2012) pmid: 22294526
107. von Bubnoff N, et al. Oncogene (2011) pmid: 20972453
108. Hochhaus A, et al. J. Cancer Res. Clin. Oncol. (2013) pmid: 24057647
109. Tabouret E, et al. Leuk. Res. (2011) pmid: 20832858
110. Dewaele B, et al. Clin. Cancer Res. (2008) pmid: 18794084
111. Weisberg E, et al. Gastroenterology (2006) pmid: 17087936
112. Brohl AS, et al. Clin Sarcoma Res (2015) pmid: 26396737
113. Grellety T, et al. Future Sci OA (2015) pmid: 28031906
114. Kollàr A, et al. Clin Sarcoma Res (2014) pmid: 25905001
115. Evans EK, et al. Sci Transl Med (2017) pmid: 29093181
116. Jaku et al., 2017; ASCO Abstract 2515
117. Debiec-Rychter M, et al. Gastroenterology (2005) pmid: 15685537
118. Heinrich MC, et al. J. Clin. Oncol. (2008) pmid: 18955451
119. Heinrich MC, et al. J. Clin. Oncol. (2008) pmid: 18955458
120. Heinrich MC, et al. Mol. Cancer Ther. (2012) pmid: 22665524
121. Heinrich MC, et al. Clin. Cancer Res. (2012) pmid: 22745105
122. Prenen H, et al. Clin. Cancer Res. (2006) pmid: 16638875
123. Score J, et al. Leukemia (2009) pmid: 18987650
124. Sorour Y, et al. Br. J. Haematol. (2009) pmid: 19466970
125. Sadovnik I, et al. Exp. Hematol. (2014) pmid: 24407160
126. von Mehren et al., 2016; ASCO Abstract 11010
127. Lierman E, et al. Leukemia (2012) pmid: 22301675
128. Grunewald S, et al. Cancer Discov (2020) pmid: 32972961
129. Paugh BS, et al. Cancer Res. (2013) pmid: 23970477
130. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
131. Hoadley KA, et al. Cell (2018) pmid: 29625048
132. Ellrott K, et al. Cell Syst (2018) pmid: 29596782
133. Taylor AM, et al. Cancer Cell (2018) pmid: 29622463
134. Gao Q, et al. Cell Rep (2018) pmid: 29617662
135. Liu J, et al. Cell (2018) pmid: 29625055
136. Sanchez-Vega F, et al. Cell (2018) pmid: 29625050
137. Song K, et al. Am J Cancer Res (2018) pmid: 29888103
138. Alentorn A, et al. Neuro-oncology (2012) pmid: 23074200
139. Sottoriva A, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23412337
140. Phillips JJ, et al. Brain Pathol. (2013) pmid: 23438035
141. Andrae J, et al. Genes Dev. (2008) pmid: 18483217
142. Semin. Oncol. (2004) pmid: 15175998
143. Ip CKM, et al. Nat Commun (2018) pmid: 30389923
144. Kang YK, et al. J Clin Oncol (2021) pmid: 34343033
145. Heinrich MC, et al. Lancet Oncol (2020) pmid: 32615108
146. Clarke ID, et al. Oncogene (2003) pmid: 12569364
147. Ozawa T, et al. Genes Dev. (2010) pmid: 20889717
148. Kalev P, et al. Cancer Cell (2021) pmid: 33450196
149. Marjon K, et al. Cell Rep (2016) pmid: 27068473
150. Mavrakis KJ, et al. Science (2016) pmid: 26912361
151. Kryukov GV, et al. Science (2016) pmid: 26912360
152. Heist et al., 2019; AACR-NCI-EORTC Abstract B116

153. Guccione E, et al. Nat. Rev. Mol. Cell Biol. (2019) pmid: 31350521
154. Fedoriw A, et al. Cancer Cell (2019) pmid: 31257072
155. Srour N, et al. Cancer Cell (2019) pmid: 31287990
156. Gao G, et al. Nucleic Acids Res. (2019) pmid: 30916320
157. Smith CR, et al. J Med Chem (2022) pmid: 35041419
158. Hansen LJ, et al. Cancer Res. (2019) pmid: 31040154
159. Tang B, et al. Cancer Res. (2018) pmid: 29844120
160. Munshi PN, et al. Oncologist (2014) pmid: 24928612
161. de Oliveira SF, et al. PLoS ONE (2016) pmid: 26751376
162. Lubin M, et al. PLoS ONE (2009) pmid: 19478948
163. Tang B, et al. Cancer Biol. Ther. (2012) pmid: 22825330
164. Collins CC, et al. Mol. Cancer Ther. (2012) pmid: 22252602
165. Bertino JR, et al. Cancer Biol. Ther. (2011) pmid: 21301207
166. Coulthard SA, et al. Mol. Cancer Ther. (2011) pmid: 21282358
167. Miyazaki S, et al. Int. J. Oncol. (2007) pmid: 17912432
168. Efferth T, et al. Blood Cells Mol. Dis. () pmid: 11987241
169. Kindler HL, et al. Invest New Drugs (2009) pmid: 18618081
170. Alhalabi O, et al. Nat Commun (2022) pmid: 35379845
171. Wei R, et al. Sci Rep (2016) pmid: 27929028
172. Zhao M, et al. BMC Genomics (2016) pmid: 27556634
173. Kirovski G, et al. Am. J. Pathol. (2011) pmid: 21356366
174. Huang HY, et al. Clin. Cancer Res. (2009) pmid: 19887491
175. Marcé S, et al. Clin. Cancer Res. (2006) pmid: 16778103
176. Meyer S, et al. Exp. Dermatol. (2010) pmid: 20500769
177. Wild PJ, et al. Arch Dermatol (2006) pmid: 16618867
178. Kim J, et al. Genes Chromosomes Cancer (2011) pmid: 21412930
179. Li CF, et al. Oncotarget (2014) pmid: 25426549
180. He HL, et al. Medicine (Baltimore) (2015) pmid: 26656376
181. Su CY, et al. Eur J Surg Oncol (2014) pmid: 24969958
182. Mirebeau D, et al. Haematologica (2006) pmid: 16818274
183. Becker AP, et al. Pathobiology (2015) pmid: 26088413
184. Snezhkina AV, et al. Oxid Med Cell Longev (2016) pmid: 27433286
185. Bistulfi G, et al. Oncotarget (2016) pmid: 26910893
186. Antonopoulou K, et al. J. Invest. Dermatol. (2015) pmid: 25407435
187. Maccioni L, et al. BMC Cancer (2013) pmid: 23816148
188. Hyland PL, et al. Int J Epidemiol (2016) pmid: 26635288
189. Lin X, et al. Cancer Sci. (2017) pmid: 27960044
190. Zhi L, et al. J Cancer (2016) pmid: 27994653
191. Gu F, et al. Br. J. Cancer (2013) pmid: 23361049
192. Limm K, et al. PLoS ONE (2016) pmid: 27479139
193. Tang B, et al. G3 (Bethesda) (2014) pmid: 25387827
194. Limm K, et al. Eur. J. Cancer (2013) pmid: 23265702
195. Stevens AP, et al. J. Cell. Biochem. (2009) pmid: 19097084
196. Limm K, et al. Eur. J. Cancer (2014) pmid: 25087184
197. Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938
198. Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521
199. Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108
200. Milella M, et al. Sci Rep (2017) pmid: 28220839
201. Galanis E, et al. J. Clin. Oncol. (2005) pmid: 15998902
202. Kreisl TN, et al. J. Neurooncol. (2009) pmid: 19018475
203. Mason WP, et al. Invest New Drugs (2012) pmid: 22160854
204. Mendes-Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735
205. Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923
206. Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244
207. McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328
208. Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130
209. Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536
210. Dougherty et al., 2014; ASCO Abstract 5536
211. Pan M, et al. Perm J (2021) pmid: 33970096
212. Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788
213. Romero I, et al. Gynecol Oncol (2020) pmid: 32988624
214. Zhou XP, et al. Int. J. Cancer (1999) pmid: 10096247
215. Rasheed BK, et al. Cancer Res. (1997) pmid: 9331072
216. Davies MP, et al. Br. J. Cancer (1999) pmid: 10188904
217. Smith JS, et al. J. Natl. Cancer Inst. (2001) pmid: 11504770
218. Lin H, et al. Clin. Cancer Res. (1998) pmid: 9796977
219. Schmidt EE, et al. J. Neuropathol. Exp. Neurol. (1999) pmid: 10560660
220. Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241
221. Furnari FB, et al. Genes Dev. (2007) pmid: 17974913
222. Yan et al. 2020; DOI:10.1200/PO.19.00385
223. Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751
224. Sano T, et al. Cancer Res. (1999) pmid: 10213484
225. Srividya MR, et al. Neuropathology (2011) pmid: 21134002
226. Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747
227. Rodríguez-Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076
228. He X, et al. Cancer Res. (2013) pmid: 23475934
229. Han SY, et al. Cancer Res. (2000) pmid: 10866302
230. Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831
231. Pradella LM, et al. BMC Cancer (2014) pmid: 24498881
232. Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651
233. Denning G, et al. Oncogene (2007) pmid: 17213812
234. Hlobilkova A, et al. Anticancer Res. () pmid: 16619501
235. Redfern RE, et al. Protein Sci. (2010) pmid: 20718038
236. Shenoy S, et al. PLoS ONE (2012) pmid: 22505997
237. Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485
238. Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519
239. Lee JO, et al. Cell (1999) pmid: 10555148
240. Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567
241. Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913
242. Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331
243. Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114
244. Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929
245. Liu J, et al. Oncogene (2014) pmid: 23995781
246. Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408
247. De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691
248. Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603
249. Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030
250. Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806
251. Gil A, et al. PLoS ONE (2015) pmid: 25875300
252. Furnari FB, et al. Cancer Res. (1998) pmid: 9823298
253. Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629
254. Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633
255. Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496
256. Andrés-Pons A, et al. Cancer Res. (2007) pmid: 17942903
257. Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158
258. Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583
259. Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208
260. Nguyen HN, et al. Oncogene (2014) pmid: 24292679
261. Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656
262. Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147
263. Wang X, et al. Biochem. J. (2008) pmid: 18498243
264. Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562
265. Nguyen HN, et al. Oncogene (2015) pmid: 25263454
266. Shan L, et al. Cell Discov (2020) pmid: 32704382
267. Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191
268. Orloff MS, et al. Oncogene (2008) pmid: 18794875
269. Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516
270. Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246
271. Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868
272. Cen L, et al. Neuro-oncology (2012) pmid: 22711607
273. Logan JE, et al. Anticancer Res. (2013) pmid: 23898052
274. Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829
275. Elvin JA, et al. Oncologist (2017) pmid: 28283584
276. Gao J, et al. Curr Oncol (2015) pmid: 26715889
277. Gopalan et al., 2014; ASCO Abstract 8077
278. Peguero et al., 2016; ASCO Abstract 2528
279. Konecny et al., 2016; ASCO Abstract 5557
280. DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126
281. Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798
282. Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767
283. Johnson DB, et al. Oncologist (2014) pmid: 24797823
284. Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101
285. Gamble LD, et al. Oncogene (2012) pmid: 21725357
286. Shapiro et al., 2013; ASCO Abstract 2500
287. Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362
288. Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312
289. Ceccarelli M, et al. Cell (2016) pmid: 26824661
290. Jonsson P, et al. Clin. Cancer Res. (2019) pmid: 31263031
291. Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251
292. Weber RG, et al. Oncogene (2007) pmid: 16909113
293. Nakamura M, et al. Brain Pathol. (2001) pmid: 11303791
294. Chakravarti A, et al. Clin. Cancer Res. (2001) pmid: 11489817
295. Feng J, et al. Cancer (2012) pmid: 21713760
296. Raabe EH, et al. Clin. Cancer Res. (2011) pmid: 21636552
297. Liu W, et al. J. Exp. Clin. Cancer Res. (2011) pmid: 21843312
298. Quelle DE, et al. Cell (1995) pmid: 8521522
299. Mutat. Res. (2005) pmid: 15878778
300. Gazzeri S, et al. Oncogene (1998) pmid: 9484839
301. Oncogene (1999) pmid: 10498883
302. Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746
303. Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699
304. Ruas M, et al. Oncogene (1999) pmid: 10498896

305. Jones R, et al. Cancer Res. (2007) pmid: 17909018
306. Haferkamp S, et al. Aging Cell (2008) pmid: 18843795
307. Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717
308. Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711
309. Gombart AF, et al. Leukemia (1997) pmid: 9324288
310. Yang R, et al. Cancer Res. (1995) pmid: 7780957
311. Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202
312. Greenblatt MS, et al. Oncogene (2003) pmid: 12606942
313. Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434
314. Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261
315. Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926
316. Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062
317. Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365
318. Koh J, et al. Nature (1995) pmid: 7777061
319. McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136
320. Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282
321. Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385
322. Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262
323. Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892
324. Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768
325. Rutter JL, et al. Oncogene (2003) pmid: 12853981
326. Itahana K, et al. Cancer Cell (2008) pmid: 18538737
327. Zhang Y, et al. Mol. Cell (1999) pmid: 10360174
328. Zhang Y, et al. Cell (1998) pmid: 9529249
329. Jafri M, et al. Cancer Discov (2015) pmid: 25873077
330. Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917
331. Adv Exp Med Biol (2010) pmid: 20687502
332. Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083
333. De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703
334. Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650
335. Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243
336. Kaufman DK, et al. Neurology (1993) pmid: 8414022
337. Bahuau M, et al. Cancer Res (1998) pmid: 9622062
338. Chan AK, et al. Clin Neuropathol () pmid: 28699883
339. Nat Rev Clin Oncol (2017) pmid: 27245281
340. Duperret EK, et al. Mol Ther (2018) pmid: 29249395
341. Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017
342. Killela PJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23530248
343. Killela PJ, et al. Oncotarget (2014) pmid: 24722048
344. Nonoguchi N, et al. Acta Neuropathol. (2013) pmid: 23955565
345. Liu X, et al. Cell Cycle (2013) pmid: 23603989
346. Koelsche C, et al. Acta Neuropathol. (2013) pmid: 24154961
347. Arita H, et al. Acta Neuropathol. (2013) pmid: 23764841
348. Reitman ZJ, et al. Acta Neuropathol. (2013) pmid: 24217890
349. Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685
350. Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118
351. Kim NW, et al. Science (1994) pmid: 7605428
352. Hanahan D, et al. Cell (2000) pmid: 10647931
353. Horn S, et al. Science (2013) pmid: 23348503
354. Huang FW, et al. Science (2013) pmid: 23348506
355. Vinagre J, et al. Nat Commun (2013) pmid: 23887589
356. Weller M, et al. Nat Rev Clin Oncol (2021) pmid: 33293629
357. Louis DN, et al. Neuro Oncol (2021) pmid: 34185076
358. Kulkarni et al., 2020; DOI: 10.1016/j.ygyno.2020.05.244
359. Hainsworth JD, et al. Clin Adv Hematol Oncol (2012) pmid: 22706484
360. Ma DJ, et al. Neuro-oncology (2015) pmid: 25526733
361. Segal et al., 2016; ISPNO Abstract EPT-21
362. Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362
363. Patterson et al., 2018; AACR Abstract 3891
364. Fumagalli et al., 2012; ESMO Abstract 1491P
365. Roubaud et al., 2012; 22294526; Schuetze et al.
366. Trent et al., 2011; ASCO Abstract 10006
367. Zustovich et al., 2013; 23898124; Reardon et al.
368. Lee EQ, et al. Neuro-oncology (2012) pmid: 23099651
369. Peereboom DM, et al. Neuro-oncology (2013) pmid: 23328813
370. Hottinger AF, et al. Br. J. Cancer (2014) pmid: 24786603
371. Karajannis MA, et al. Neuro-oncology (2014) pmid: 24803676
372. Sarkaria JN, et al. Clin. Cancer Res. (2010) pmid: 20921209
373. Lassen U, et al. Anticancer Res. (2013) pmid: 23564811
374. Geoerger B, et al. Eur. J. Cancer (2012) pmid: 22033322
375. Wen PY, et al. Neuro-oncology (2014) pmid: 24470557
376. Metzgeroth G, et al. Leukemia (2007) pmid: 17377585
377. Farag et al., 2016; ASCO Abstract 11011
378. Piovesan et al., 2009; ASCO Abstract 10565
379. Raut et al., 2015; ASCO Abstract 10537
380. Hassler MR, et al. Springerplus (2014) pmid: 25674429
381. Razis E, et al. Clin. Cancer Res. (2009) pmid: 19789313
382. Reardon DA, et al. Br. J. Cancer (2009) pmid: 19904263
383. Reardon DA, et al. Cancer (2012) pmid: 22371319

Electronically signed by Erik Williams, M.D. | 15 September 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531